Vertex unfazed by competitive IgAN space as FDA verdict looms
Rather than feel pressured by how well rivals are doing, Vertex Pharmaceuticals’ CEO Reshma Kewalramani is encouraged by the competition in the IgA nephropathy space—and sees good opportunity for the big biotech’s upcoming drug povetacicept. The strong …